MARKET

ZVRA

ZVRA

Zevra Therapeutics Inc
NASDAQ
5.85
-0.26
-4.26%
After Hours: 5.80 -0.05 -0.85% 17:56 07/12 EDT
OPEN
6.20
PREV CLOSE
6.11
HIGH
6.20
LOW
5.75
VOLUME
574.98K
TURNOVER
0
52 WEEK HIGH
7.28
52 WEEK LOW
3.890
MARKET CAP
244.84M
P/E (TTM)
-4.3533
1D
5D
1M
3M
1Y
5Y
1D
Zevra Therapeutics Announces Key Agreement Updates and Stock Offering
TipRanks · 1d ago
ZEVRA THERAPEUTICS: UNDER AGREEMENT, MAY OFFER & SELL FROM TIME TO TIME SHARES OF ITS COMMON STOCK HAVING OFFERING PRICE OF UP TO $75 MLN
Reuters · 1d ago
ZEVRA THERAPEUTICS: ENTERED INTO AN EQUITY DISTRIBUTION AGREEMENT WITH CITIZENS JMP SECURITIES LLC
Reuters · 1d ago
Zevra Therapeutics, Inc.'s (NASDAQ:ZVRA) 26% Jump Shows Its Popularity With Investors
Zevra Therapeutics, Inc. Share price is up 26% in the last month. The company's price-to-sales ratio of 9.2x is higher than most in the Pharmaceuticals industry. The high P/S might be a sign of confidence in the company's future growth. ZevraTherapeutics has a superior revenue growth rate compared to the industry.
Simply Wall St · 1d ago
Zevra (ZVRA) Rises on Update on Niemann-Pick Disease Type C Drug
NASDAQ · 3d ago
FDA Convenes Expert Panel Meeting For Zevra Therapeutics' Arimoclomol, Analyst Optimistic About Approval Despite Small Patient Base
Zevra Therapeutics Inc.’s arimoclomol for Niemann-Pick disease type C (NPC) is expected to be reviewed by the FDA in September. The company acquired arimclomol from Orphazyme for $12.8 million. William Blair reiterates the Outperform rating for Zevra.
Benzinga · 4d ago
Zevra Therapeutics Price Target Maintained With a $15.00/Share by HC Wainwright & Co.
Dow Jones · 4d ago
HC Wainwright & Co. Reiterates Buy on Zevra Therapeutics, Maintains $15 Price Target
Benzinga · 4d ago
More
About ZVRA
Zevra Therapeutics, Inc. is a rare disease company science, data, and patients need to create transformational therapies for diseases with limited or no treatment options. The Company has a diverse portfolio of products and product candidates, which includes a combination of both a clinical stage pipeline and commercial stage assets. Its pipeline includes arimoclomol, an orally delivered, investigational product candidate being developed for Niemann-Pick disease type C (NPC). KP1077 is the Company's lead clinical development product candidate which is being developed as a treatment for idiopathic hypersomnia (IH), a rare neurological sleep disorder, and narcolepsy. Its commercial product, AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder (ADHD), in patients aged six years and older containing its prodrug, serdexmethylphenidate (SDX), and d-methylphenidate (d-MPH). Its other commercial product is OLPRUVA.

Webull offers Zevra Therapeutics Inc stock information, including NASDAQ: ZVRA real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ZVRA stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ZVRA stock methods without spending real money on the virtual paper trading platform.